Mathini Ilancheran

Mathini Ilancheran


  • India’s New Drugs, Medical Devices, And Cosmetics Draft Bill 2022

    To accommodate changing requirements and encourage the adoption of new technology, India’s Ministry of Health and Family Welfare released a draft bill in July 2022 to replace the existing Drugs and Cosmetics Act 1940. What are the major areas of change and how much of an impact will there be?

  • COVID-19’s Impact On Availability Of Drugs And API From India And China

    COVID-19 has caused an increase in demand for APIs and drugs; those used as antimalarials are seeing the highest demand, followed by bronchodilators, antibiotics, and antivirals. This article reviews the drugs and API in demand globally, with assessments of their supply status in India and China.

  • COVID-19, Medical Drones, & The Last Mile Of The Pharma Supply Chain

    During crises like this pandemic, bottlenecks in drug distribution and sample testing can be improved through automation, artificial intelligence, and robotics. This article provides an overview of the medical drone industry, with a particular emphasis on its adoption by the pharmaceutical sector to solve logistical problems in healthcare during times of heightened need. 

  • Human Biological Samples Sourcing: An Overview

    Human Biological Samples (HBS) are collected during a biopsy or surgery to diagnose the patient and are preserved for later use by researchers to study the disease progression to bring about potential benefits to the patient community. Despite the varying regulations, HBS collection and biobanking has evolved throughout the years. This whitepaper discusses the trends, supplier landscape, and segmentation by providing visibility to the HBS market and the benefits of engaging with a commercial vs. public biobank.